Cedara reduces liabilities

Article

Slowly but surely, Cedara Software is working to put its financial troubles to rest. The Canadian company has settled with certain holders of promissory notes, exchanging the notes

Slowly but surely, Cedara Software is working to put its financial troubles to rest. The Canadian company has settled with certain holders of promissory notes, exchanging the notes for 1.4 million shares of common stock and, in the process, cutting its liabilities by US$3.5 million. The company is negotiating with the remaining note holders to convert about US$3.6 million of debt into company equity. Meanwhile, Cedara has agreed with Carl Zeiss and its affiliates to settle certain financial and other contractual obligations. The agreement provides for a cash settlement of US$1.5 million to Zeiss, paid out over the course of 18 months commencing April 30, and for Cedara to provide US$1.5 million of software licenses and engineering services to Zeiss at no charge. The settlement agreement also provides that, following the provision of this software, both companies will enter into negotiations for Cedara to become a preferred OEM software supplier to a medical division of Zeiss. Cedara has also entered into an agreement under which Medtronic Surgical Navigation Technologies will purchase certain assets owned by Cedara's subsidiary, Surgical Navigation Specialists, related to its image-guided surgery business. Medtronic SNT will offer SNS customers support and a migration path to new Medtronic SNT image-guided systems.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.